Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second– and later lines)—PD-L1 inhibitor Tecentriq (Roche/Genentech/Chugai) followed by PD-1 inhibitor Opdivo (Bristol-Myers Squibb) and other PD-1/PD-L1 inhibitors—significant sales are forecast for the unresectable locally advanced or metastatic setting. There is now intense Phase II/III pipeline activity, with some drugs in the late-phase pipeline also targeting previously untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options.
- How large are the clinically and commercially relevant drug-treatable unresectable locally advanced or metastatic bladder cancer populations and how will drug-treatment rates change over time?
- What is the current state of treatment for unresectable locally advanced or metastatic bladder cancer? What are the (dis)advantages of currently marketed drugs and interviewed experts’ insights on these therapies?
- What clinical needs remain unfulfilled and what opportunities can developers capitalize on?
- What pipeline products are most promising, and what sales/uptake could they secure in the unresectable locally advanced or metastatic bladder cancer market? What are the most promising early-phase pipeline products?
- What are the drivers and constraints in the unresectable bladder cancer market, and how will the market evolve over the ten-year forecast period within the major markets?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.